AInvest★★★★★3-DAY FREE
Catch pre-market movers with AI signals.
Claim Trial
--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About KURA20260918C14
Biotechnology Ⅲ
Kura Oncology, Inc., was originally incorporated in Delaware in November 2007. They are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine to treat cancer. Their pipeline consists of small molecule product candidates targeting cancer signaling pathways where there are strong scientific and clinical reasons to improve outcomes, which they intend to combine with molecular or cellular diagnosis to identify patients most likely to respond to treatment. They are conducting clinical trials on three product candidates: ciftominib, tipifarnib and KO-2806.
